Kyowa Hakko Kirin’s first and only Rituxan (rituximab) biosimilar in Japan is showing a faster-than-expected uptake in the market, with the company racking up 4.3 billion yen from the cancer drug in 2018, far beyond its initial 3.2 billion yen…
HOME > ORGANIZATION
ORGANIZATION
- 2019 Is Year to “Get Things Right”: PhRMA Japan Chairman
February 8, 2019
- Sanofi CEO Becomes Chairman of PhRMA
February 6, 2019
- PhRMA Takes Issue with Japan Govt’s Overreliance on ICER, Proposes Point-Based Appraisal Framework
February 5, 2019
- JPMA Lays Out Policy Proposal 2019, Advocates Pricing Premium for Drugs Used for Pregnant Women
January 25, 2019
- Think Tank Urges Govt to Look at Drugs with Large Prescription Volumes Too
January 25, 2019
- Regional Formulary Initiatives Underway, Eyes on Cost Control for Branded Drugs with No Gx
January 22, 2019
- Don’t Cause Disruptions in Drug Distribution with October Re-Pricing: Japan Wholesaler Chief
January 15, 2019
- Budget Juggling Dependent on Drug Price Cuts Unacceptable: Tokyo Pharma Chief
January 9, 2019
- Generic Use Rate at 73.2% in July-September: JGA
December 27, 2018
- JMA Chief Pushes September 2019 Drug Price Announcement for Ad-Hoc Revision
December 27, 2018
- Use of Generics and Formulary Would Reduce Drug Expenditure by 38%: Payer Estimate
December 27, 2018
- March Announcement of NHI Price List “Not an Option”, Says Wholesaler Group
December 25, 2018
- October 2019 Drug Price Revision a Relief for JPMA: Official
December 25, 2018
- Pharma Companies Mull Use of Tohoku University’s Database for Drug Discovery: JPMA Official
December 18, 2018
- Lilly’s Jonsson to Stay as PhRMA Japan Chief
December 13, 2018
- 9 EFPIA Companies Reviewed Headcount Planning after Drug Pricing Overhaul: Survey
December 5, 2018
- JPMA Chief Warns against Japan Govt’s Short-Sighted Budgeting, Calls for Longer-Term View on Innovation
November 26, 2018
- 8 Infectious Disease-Related Societies Launch New Organization to Combat Drug-Resistance Problem
November 12, 2018
- 7 EFPIA Companies Revised R&D Strategies after April Pricing Overhaul: Survey
November 9, 2018
- Wrong Policies Could Drive Investments Out of Japan amid China’s Rise, PhRMA Int’l Advocacy Chief Warns
November 6, 2018
ページ
Members of a key reimbursement policy panel appear to be becoming more and more open to the industry’s call for…
With a cursory glance, recruitment is easily defined. We’re here to help place candidates into the vacancies our clients need to fill. Armed with a pen and paper, you could even map out the process.• We study the market• We…
As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…